Considerations for Using Immune Therapy in Treating Metastatic Non-Small Cell Lung Cancer

Recent advances in immune therapy for patients with non-small cell lung cancer (NSCLC) have taken a long-awaited step forward and shifted the standard of care of patients with advanced and metastatic disease.

The goal of this activity is to provide participants with knowledge to assist in evaluating the efficacy and safety of immunotherapies, implement genetic screening, and formulate individualized treatment plans for patients with metastatic NSCLC.

Target Audience

This activity is designed for oncology healthcare providers (oncologists, oncology nurses, and oncology physician assistants) who care for patients with NSCLC. No prerequisites required.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to:

  • After participating in this activity, the participant will demonstrate the ability to:
  • EVALUATE the efficacy and safety of immunotherapy as part of NSCLC treatment paradigms.
  • FORMULATE individualized treatment plans for NSCLC using patient case scenarios.
Additional information
Contact email: 
webmaster@asimcme.com
Course summary
Available credit: 
  • 0.50 ANCC
Registration opens: 
11/18/2016
Registration closes: 
11/19/2018
Cost:
$0.00
Part of: 
Journal | Oncology Consult

Chair, Planner, and Faculty
David S. Ettinger, MD
Alex Grass Professor in Oncology
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

 

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Available Credit

  • 0.50 ANCC

Price

Cost:
$0.00
Please login or register to take this course.